Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New FDA Web Page Aims To Clarify Position On 3D Printing

Executive Summary

As industry awaits more guidance and clarification from US FDA about its regulatory oversight of 3D-printed devices, the agency is attempting to be more transparent with a new web page that outlines some of its current thinking and efforts on the topic.

You may also be interested in...



3D Printing Opens A Legal Brave New World

Attorneys at Reed Smith have released a white paper that attempts to tackle the legal uncertainties facing 3D printing of medical devices. They tackle issues including product liability, intellectual property and quality management. Also: Listen to our podcast interview with one key contributor to the report.

FDA Tackles 3-D Printing Considerations In Draft Guidance

A draft guidance issued by FDA on additive manufacturing, or 3-D printing, of medical devices is meant to be a starting point for an industry that is growing exponentially. The document outlines recommendations on topics such as device design, software considerations and material testing requirements.

Report: Boom In 3D-Printed Medical Devices By 2022

A new market report estimates the global health-care revenue from 3D-printed medical devices is likely to grow to almost $3 billion by 2022. FDA has a keen interest in understanding how to oversee production of 3D-printed devices that can be made anywhere, and device-makers are interested in the technology to develop products personalized to patients.

Topics

UsernamePublicRestriction

Register

SC143420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel